Frequently Asked Questions

Fragile X DNA testing is funded by Medicare under the following conditions:

  • Medicare item 73300 in the following circumstances: detection of genetic mutation of the FMR1 gene by nucleic acid amplification (NAA) where:

(a) The patient exhibits intellectual disabilities, ataxia, neurodegeneration, or premature ovarian failure consistent with a FMR1 mutation; or

(b) The patient has a relative with the FMR1 mutation.

  • Medicare item 73305: Detection of genetic mutation of the FMR1 gene southern blot where the results in item 73300 are inconclusive.

Please check with Medicare if you have any concerns.

Share:
Menu
Menu